Back to CVE records
Medium 5.3Published Apr 2, 2026

CVE-2026-5323A vulnerability was found in priyankark a11y-mcp up to 1.0.5.

Updated under an hour ago ()

Does this affect you?

It lists no affected products yet. Add what you run and Signals checks it as products are added.

No exploitation reported and no EPSS estimate yet.

A vulnerability was found in priyankark a11y-mcp up to 1.0.5. This vulnerability affects the function A11yServer of the file src/index.js. The manipulation results in server-side request forgery. The attack must be initiated from a local position. The exploit has been made public and could be used. This product operates on a rolling release basis, ensuring continuous delivery. Consequently, there are no version details for either affected or updated releases. Upgrading to version 1.0.6 is able to resolve this issue. The patch is identified as e3e11c9e8482bd06b82fd9fced67be4856f0dffc. It is recommended to upgrade the affected component. The vendor acknowledged the issue but provides additional context for the CVSS rating: "a11y-mcp is a local stdio MCP server - it has no HTTP endpoint and is not network-accessible. The caller is always the local user or an LLM acting on their behalf with user approval."

CVSS
5.3 MEDIUM (v3.1, NVD)CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
Weakness (CWE)
CWE-918
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Deferred
Record last updated
Jun 17, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

No affected products are listed yet.

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.